Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II

NCT00856804 is registered in ClinicalTrials.gov with Valme University Hospital as lead sponsor.

NCT NCT00856804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00856804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II
Lead sponsor
Valme University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2009
Completion date
June 30, 2012
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c